** Shares of therapy developer Immuneering IMRX.O rise 38.5% to $12.78 in extended trade

** Company says its therapy, IMM-1-104, showed an overall response rate of 86% in combination with gemcitabine during a mid-stage trial over 9 months of treatment in patients with pancreatic cancer

** Co expects regulatory feedback on the trial plans in Q4

** Separately, IMRX says that Sanofi SASY.PA has agreed to purchase $25 million of its shares in a private placement transaction that is expected to close concurrently with the offering

** Company intends to use the net proceeds to advance the preclinical and clinical development of its product candidates

** As of last close, stock more than tripled YTD

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))